EUVIMEDEUVIMED entdecken
Open Access

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models

Sumer Jasmine, Adel Mandl, Timothy E G Krueger, Susan L Dalrymple, Lizamma Antony, Jennifer Dias, Cassandra A Celatka, Amy E Tapper, Maria Kleppe, Mayuko Kanayama, Yuezhou Jing, Valentina Speranzini und 9 weitere

The Prostate · 2024

DOI: 10.1002/pros.24707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Sumer Jasmine und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Histone Demethylases, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genetech DMPK Scholarship, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Lysine‐specific demethylase 1 (LSD1) is emerging as a critical mediator of tumor progression in metastatic castration‐resistant prostate cancer (mCRPC). Neuroendocrine prostate cancer (NEPC) is increasingly recognized as an adaptive mechanism of resistance in mCRPC patients failing androgen receptor axis‐targeted therapies. Safe and effective LSD1 inhibitors are necessary to determine antitumor response in prostate cancer models. For this reason, we characterize the LSD1 inhibitor bomedemstat to assess its clinical potential in NEPC as well as other mCRPC pathological subtypes.

Methods

Bomedemstat was characterized via crystallization, flavine adenine dinucleotide spectrophotometry, and enzyme kinetics. On‐target effects were assessed in relevant prostate cancer cell models by measuring proliferation and H3K4 methylation using western blot analysis. In vivo, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of bomedemstat are also described.

Results

Structural, biochemical, and PK/PD properties of bomedemstat, an irreversible, orally‐bioavailable inhibitor of LSD1 are reported. Our data demonstrate bomedemstat has >2500‐fold greater specificity for LSD1 over monoamine oxidase (MAO)‐A and ‐B. Bomedemstat also demonstrates activity against several models of advanced CRPC, including NEPC patient‐derived xenografts. Significant intra‐tumoral accumulation of orally‐administered bomedemstat is measured with micromolar levels achieved in vivo (1.2 ± 0.45 µM at the 7.5 mg/kg dose and 3.76 ± 0.43 µM at the 15 mg/kg dose). Daily oral dosing of bomedemstat at 40 mg/kg/day is well‐tolerated, with on‐target thrombocytopenia observed that is rapidly reversible following treatment cessation.

Conclusions

Bomedemstat provides enhanced specificity against LSD1, as revealed by structural and biochemical data. PK/PD data display an overall safety profile with manageable side effects resulting from LSD1 inhibition using bomedemstat in preclinical models. Altogether, our results support clinical testing of bomedemstat in the setting of mCRPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone DemethylasesProstatic Neoplasms, Castration-ResistantMaleHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysAntineoplastic AgentsEnzyme InhibitorsBenzamidesPiperazinesTriazoles

Stichwörter der Autor:innen

LSD1MAONEPCepigeneticsmCRPCneuroendocrine

Substanzen

Histone DemethylasesKDM1A protein, humanAntineoplastic AgentsEnzyme InhibitorsbomedemstatBenzamidesPiperazinesTriazoles

Autor:innen und Institutionen

  • Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Imago Biosciences Inc., A Subsidiary of Merck & Co, Inc., San Francisco, California, USA.
  • Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
  • Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Yuzhuo Z Wang, Samuel R Denmeade, John T Isaacs, W Nathaniel Brennen

Förderung

  • NCI NIH HHS
  • Genetech DMPK Scholarship
  • NIGMS NIH HHS
  • US Department of Defense
  • PhRMA Foundation Pre-doctoral Fellowship
  • Imago BIosciences
  • NIH HHS
  • European Association for Cancer Research

Zitieren

APA

Jasmine, S., Mandl, A., Krueger, T. E. G., Dalrymple, S. L., Antony, L., Dias, J., Celatka, C. A., Tapper, A. E., Kleppe, M., Kanayama, M., Jing, Y., Speranzini, V., Wang, Y. Z., Luo, J., Trock, B. J., Denmeade, S. R., Carducci, M. A., Mattevi, A., Rienhoff, H. Y., …, & Brennen, W. N. (2024). Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. The Prostate. https://doi.org/10.1002/pros.24707

Vancouver

Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, et al. Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models. The Prostate. 2024. doi:10.1002/pros.24707

BibTeX
@article{Jasmine2024,
  author = {Jasmine, Sumer and Mandl, Adel and Krueger, Timothy E G and Dalrymple, Susan L and Antony, Lizamma and Dias, Jennifer and Celatka, Cassandra A and Tapper, Amy E and Kleppe, Maria and Kanayama, Mayuko and Jing, Yuezhou and Speranzini, Valentina and Wang, Yuzhuo Z and Luo, Jun and Trock, Bruce J and Denmeade, Samuel R and Carducci, Michael A and Mattevi, Andrea and Rienhoff, Hugh Y and Isaacs, John T and Brennen, W Nathaniel},
  title = {Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24707}
}
Kostenlos starten →